Skip Standard Navigation Links
Centers for Disease Control and Prevention
 CDC Home Search Health Topics A-Z
peer-reviewed.gif (582 bytes)
eid_header.gif (2942 bytes)
Past Issue

Vol. 11, No. 9
September 2005

Adobe Acrobat logo

EID Home | Ahead of Print | Past Issues | EID Search | Contact Us | Announcements | Suggested Citation | Submit Manuscript

PDF Version | Comments Comments | Email this article Email this article



Acknowledgments
References
Table

Letter

West Nile Virus Antibodies in Colombian Horses

Salim Mattar,* Eric Edwards,† Jose Laguado,* Marco González,* Jaime Alvarez,* and Nicholas Komar†Comments
*University of Córdoba, Montería, Córdoba, Colombia; and †Centers for Disease Control and Prevention, Fort Collins, Colorado, USA

Suggested citation for this article


To the Editor: West Nile Virus (WNV) is rapidly spreading in the Western Hemisphere (1). We report the first evidence for WNV transmission in South America.

WNV is serologically related to the Japanese encephalitis complex of flaviviruses (Flaviviridae), which includes Saint Louis encephalitis virus (SLEV) (in North and South America), Japanese encephalitis virus (Asia), and Murray Valley encephalitis virus (Australia) (2). Because of antigenic cross-reactivity within this complex, WNV serologic diagnosis requires highly specific assays, such as the plaque-reduction neutralization test (PRNT) (3). We used PRNT to evaluate serum collected from 130 healthy equines (horses and donkeys) in Colombia, where WNV had not been previously reported. These equines were sampled between September 15 and October 29, 2004, in the northern departments of Córdoba and Sucre in the Caribbean region of Colombia. Samples were heat-inactivated and titrated by PRNT for antibodies to WNV, SLEV, and 3 other South American flaviviruses: Rocio, Ilhéus, and Bussuquara. Twelve specimens (9%) from 10 different premises tested positive for WNV (Table). None of these animals had been vaccinated against WNV or had traveled outside of the region. An equine immunoglobulin (Ig) M-capture enzyme-linked immunosorbent assay (ELISA) that used WNV antigen detected anti-WNV IgM in 2 of the 12 specimens, which indicated that some of these infections were relatively recent (probably within 3 months of sampling). The positive findings in both Córdoba and Sucre were corroborated by a WNV-specific blocking ELISA (4). Numerous other samples exhibited flavivirus reactivity in the neutralization and blocking ELISA assays, mostly because of SLEV. Complete test results from these horses, as well as from Colombian cattle and chickens, will be presented elsewhere.

These serologic data should be considered indirect evidence of WNV activity in Colombia. We encourage Colombian human and animal health authorities to enhance surveillance for human, equine, and avian disease attributable to WNV. Efforts are needed to isolate the virus or detect specific viral RNA to confirm this finding and to identify vectors and vertebrate hosts involved in WNV transmission in Colombia.

Acknowledgments

We thank Robert Lanciotti, Janeen Laven, Jason Velez, and Vanesa Otero for technical assistance.

References

  1. Komar N. West Nile virus: epidemiology and ecology in North America. Adv Virus Res. 2003;61:185–234.
  2. Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, Westaway EG, et al. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol. 1989;70:37–43.
  3. Beaty BJ, Calisher CH, Shope RE. Arboviruses. In: Lennette EH, Lennette DA, Lennette ET, editors. Diagnostic procedures for viral, rickettsial, and chlamydial infections. 7th ed. Washington: American Public Health Association; 1995. p. 189–212.
  4. Blitvich BJ, Marlenee NL, Hall RA, Calisher CH, Bowen RA, Roehrig JT, et al. Epitope-blocking enzyme-linked immunosorbent assays for the detection of serum antibodies to West Nile virus in multiple avian species. J Clin Microbiol. 2003;41:1041–7.

 

Table. PRNT90 antibody titers to WNV and other South American flaviviruses for Colombian equine sera*†


Equine ID‡

Department

Age (y)

WNV

SLEV

ILHV

ROCV

BSQV


3

Córdoba

4

1:40

<1:10

<1:10

<1:10

<1:10

35

Córdoba

5

1:160

<1:10

<1:10

<1:10

<1:10

39§

Córdoba

4

1:40

<1:10

<1:10

<1:10

<1:10

41

Córdoba

6

1:40

<1:10

<1:10

<1:10

<1:10

48

Córdoba

4

1:640

<1:10

<1:10

<1:10

<1:10

76

Sucre

5

1:80

<1:10

<1:10

<1:10

<1:10

85

Sucre

9

1:80

<1:10

<1:10

<1:10

<1:10

94

Sucre

3

1:40

<1:10

<1:10

<1:10

<1:10

101

Sucre

4

1:40

<1:10

<1:10

<1:10

<1:10

109§

Sucre

7

1:160

1:40

1:40

1:10

<1:10

123

Córdoba

6

1:40

<1:10

<1:10

<1:10

<1:10

125

Córdoba

4

1:160

<1:10

<1:10

<1:10

<1:10


*These 12 specimens were considered positive for WNV infection; a 4-fold WNV PRNT90 titer compared to that of other flaviviruses was required for a positive determination of previous WNV infection.

†PRNT90, 90% plaque reduction neutralization test; WNV, West Nile virus; SLEV, Saint Louis encephalitis virus (South American strain); ILHV, Ilhéus virus; ROCV, Rocio virus; BSQV, Bussuquara virus.

‡All equines were horses except for 76 and 85, which were donkeys.

§Also positive for anti-WNV immunoglobulin M by antibody-capture enzyme-linked immunosorbent assay.

 

Suggested citation for this article:
Mattar S, Edwards E, Laguado J, González M, Alvarez J, Komar N. West Nile virus antibodies in Colombian horses [letter]. Emerg Infect Dis [serial on the Internet]. 2005 Sep [date cited]. Available from http://www.cdc.gov/ncidod/EID/vol11no09/05-0426.htm

   
     
   
Comments to the Authors

Please use the form below to submit correspondence to the authors or contact them at the following address:

Nicholas Komar, Centers for Disease Control and Prevention, PO Box 2087, Fort Collins, CO 80522, USA; fax: 970-221-6476; email: nck6@cdc.gov

Please note: To prevent email errors, please use no web addresses, email addresses, HTML code, or the characters <, >, and @ in the body of your message.

Return email address optional:


 


Comments to the EID Editors
Please contact the EID Editors at eideditor@cdc.gov

Email this article

Please note: To prevent email errors, please use no web addresses, email addresses, HTML code, or the characters <, >, and @ in the body of your message.

Your email:

Your friend's email:

Message (optional):

 

 

 

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page posted August 8, 2005
This page last reviewed August 19, 2005

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention